Chinese herbal medicine Shufeng Jiedu capsule for patients with mild to moderate COVID-19
| ISRCTN | ISRCTN14236594 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN14236594 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Nil known |
| Sponsors | Department of Science and Technology of Anhui Province, Anhui Jiren Pharmaceutical Co. LTD |
| Funders | Science and Technology Department of Anhui Province, Anhui Jiren Pharmaceutical Co. LTD |
- Submission date
- 29/04/2022
- Registration date
- 03/05/2022
- Last edited
- 25/06/2024
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
Shufeng Jiedu capsule has the effect of dissipating wind, clearing heat, detoxifying and benefiting the pharynx (based on traditional Chinese medicine theory), so it can relieve the symptoms of COVID-19 patients and reduce their hospital stay. Thus, this study aims to find whether the Shufeng Jiedu capsule can help patients with mild coronavirus disease 2019 to relieve the symptoms and reduce their hospital stay.
Who can participate?
COVID-19 patients who are willing to take traditional Chinese medicine will be treated at designated isolation hospitals.
What does the study involve?
Participants will be randomly allocated to one of two groups a Shufeng Jiedu capsule or placebo for 5 days. After 5 days, they were followed up for 14 days after discharge.
Participants will be asked to give blood samples at the beginning of the study, on the 3rd day and on the 6th day to ensure basic safety. Participants will get 5-days of treatment and will complete the online questionnaires and assessments every day to ensure the effectiveness of symptoms.
What are the possible benefits and risks of participating?
Participants will get 5-day treatment for COVID-19. Medicines are provided free of charge. Diarrhea, loose stools and yellow urine may occur after taking the medicine.
Where is the study run from?
The third people's hospital of Shenzhen, China.
The people's hospital of Bozhou, China.
When is the study starting and how long is it expected to run for?
April 2022 to September 2022
Who is funding the study?
Science and Technology Department of Anhui Province (China) and Anhui Jiren Pharmaceutical Co. LTD.
Who is the main contact?
1. PhD. Chun-li Lu
Jennylu@bucm.edu.cn
2. PhD. Xue-han Liu
xuehan_liu@foxmail.com
3. Prof. Jian-ping Liu
Liujp@bucm.edu.cn
Contact information
Principal investigator
11 Beisanhuan Dong Lu
Chaoyang District
Beijing
100029
China
 ORCID ID |
0000-0002-0320-061X |
|---|---|
| Phone | +86 10-64286760 |
| Liujp@bucm.edu.cn |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicenter randomized double-blind placebo-controlled clinical trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Chinese herbal medicine Shufeng Jiedu capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): A randomized double-blind placebo-controlled clinical trial |
| Study objectives | Shufeng Jiedu capsule has the effect of dissipating wind, clearing heat, detoxifying and benefiting the pharynx (based on traditional Chinese medicine theory), so it can relieve the symptoms of COVID-19 patients and reduce their time during their hospital stay. |
| Ethics approval(s) | Approved 29/04/2022, Ethics Committee of the third people's hospital of Shenzhen (29 Bujibulan Road, Longgang District, Shenzhen, China; +86 0755-61222333-6539; szdsrmyyec@163.com), ref:[2022-097] |
| Health condition(s) or problem(s) studied | COVID-19 (SARS-CoV-2 infection) |
| Intervention | Experimental group: Shufeng Jiedu Capsule, taken orally for 5 days. Control group: Shufeng Jiedu placebo, taken orally for 5 days. After 5 days of treatment, all participants are no longer taking any Traditional Chinese medicine. Participants were followed up for 14 days after discharge. Participants are randomly allocated to groups using the coded boxes of pills. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Shufeng Jiedu Capsule |
| Primary outcome measure(s) |
Time to alleviation of symptoms (TTAS). Clinical symptoms are based on flu-like associated symptoms, including cough, stuffy nose, sore throat, fever or chills, muscle/joint pain, headache, and fatigue measured using self-report on a 0-3 scale (0 as no symptoms, 1 as mild symptoms, 2 as moderate symptoms and 3 as severe symptoms) at baseline, every day during the intervention (from 1st-6th day), and every day during follow-up (since discharged from hospital until 14th day). |
| Key secondary outcome measure(s) |
1. Relief time and relief rate of other symptoms (other symptoms are determined according to the epidemic symptoms of COVID-19, including fever, respiratory symptoms (shortness of breath, dry throat, runny nose, etc.), and systemic symptoms (diarrhea, loss of appetite, body pain, smell, taste, nausea) measured scores from 0-3 (0 as no symptoms, 1 as mild symptoms, 2 as moderate symptoms and 3 as severe symptoms) at baseline, every day during the intervention (from 1st-6th day), and every day during follow-up (since discharged from hospital until 14th day). |
| Completion date | 30/09/2022 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 400 |
| Total final enrolment | 407 |
| Key inclusion criteria | 1. Meet the mild and common diagnostic criteria for COVID-19; 2. The time interval between symptom onset and random enrollment was less than 3 days; 3. Adults (≥18 and ≤75 years); 4. Agree to participate in this study and accept random grouping; 5. Those who have signed informed consent and are not currently participating in other clinical trials of traditional Chinese medicine for COVID-19 |
| Key exclusion criteria | 1 Female patients in pregnancy and lactation; 2 Patients with a history of allergy to the test drug ingredients; 3. As judged by the investigator, or patients with acute episodes, cognitive insufficiency, or severe diarrhea (resulting in electrolyte disturbances and dehydration); 4. Continuous use of traditional Chinese medicine (tripartite and three-drug treatment) for COVID-19 within 3 days before enrollment; 5. Patients who are also participating in other clinical trials. |
| Date of first enrolment | 03/05/2022 |
| Date of final enrolment | 15/09/2022 |
Locations
Countries of recruitment
- China
Study participating centres
Shenzhen
518112
China
Bozhou
236814
China
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not expected to be made available |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available now due to the ethical requirement |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | 27/05/2024 | 25/06/2024 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
25/06/2024: Publication reference and total final enrolment added.
03/05/2022: Trial's existence confirmed by Ethics Committee of the third people's hospital of Shenzhen.
